On Apr 16, 2018 Clementia Pharmaceuticals Inchares (NASDAQ:CMTA) Sellers Strengthened Their Shorts By 271.27%

April 16, 2018 - By Anthony Romero

It was recorded an increase on Clementia Pharmaceuticals Inchares (NASDAQ:CMTA)’s shares shorted with 271.27%. It was published in April by FINRA the 903,300 shares shorted on CMTA. Previously was reported up change of 271.27% from 243,300 shares. 11 days will cost CMTA With 80,500 average volume to recover its previous position.

On during the last trading session the stock increased $1.19 or 7.63%, reaching $16.79.Currently Clementia Pharmaceuticals Inc. is after 0.00% change in last April 16, 2017. CMTA has 7,972 shares volume. CMTA underperformed the S&P500 by 11.55%.

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases.The firm is worth $532.54 million. The Company’s lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models.Last it reported negative earnings. The firm is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: